Sharp Fluidics Clinical Study, Efficacy of a Novel Intraoperative Engineered Sharps Injury Prevention Device: Pilot Usability and Efficacy Trial, Published in JMIR Perioperative Medicine

December 22, 2020

Sharp Fluidics reports the first prospective, case-controlled clinical study of an Engineered Sharps Injury Prevention (ESIP) device to prevent Needle Stick Injuries (NSI) in an operating room demonstrated that the use of Operative Armour®, a wearable needle safety and workflow efficiency device, reduces surgical needle passes and handling during surgical closure.

This study, “Efficacy of a Novel Intraoperative Engineered Sharps Injury Prevention Device: Pilot Usability and Efficacy Trial,” Jenny Hillary, M.D., et al. conducted at The Johns Hopkins University School of Medicine, was published in JMIR Perioperative Medicine.

In the 100-patient study, 50 procedures were performed using Operative Armour and 50 control procedures without.  The procedures performed were in Plastics Surgery including abdominal surgery, breast reconstruction, and mastopexy/breast reduction or revisions.  During these procedures, Operative Armour resulted in as many as half the needle adjustments by hand.

“In this study at Johns Hopkins it was found that Operative Armour functions effectively as an engineered Sharps Injury Prevention device by decreasing intraoperative needle passing and handling”, said Douglas Rimer, President of Sharp Fluidics.  “The authors stated, ‘By minimizing sharps behaviors that drive needle stick injuries such as manipulation, handling, and passing of intraoperative sharps, Operative Armour demonstrates superiority over the current practice in the potential to significantly decrease sharp injuries.  We anticipate an associated decrease in needlestick injuries with the use of the device.'”

Other observations by the authors included the potential for OR efficiency gains, “In addition to the device’s impact on needlestick risk, it may also have the potential to improve efficiency by introducing parallel processing in which two or more separate processes are conducted simultaneously rather than in series.” While the surgeon is closing independently, managing their own sutures, the circulator and scrub-tech can focus on performing their final count and breaking down the room, eliminating conflict between these two equally important activities.

The study concluded that Operative Armour effectively functions as an ESIP device by decreasing intraoperative needle passing and handling.  With over 88,000 operating room needlestick injuries in the US each year, Operative Armour provides a new option to help keep Surgeons, Nurses, and other medical staff safer in the operating room.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”